Bioventus Reaches Milestone with 2 Million DUROLANE® Treatments Worldwide
22.9.2020 17:30:00 EEST | Business Wire | Press release
Bioventus, a global leader in Innovations For Active Healing, is celebrating a milestone and recognizing more than 2 million treatments worldwide with DUROLANE, its single-injection, hyaluronic acid (HA) product used in the treatment of pain associated with osteoarthritis (OA). DUROLANE is the original single injection hyaluronic acid therapy, has helped patients in nearly 30 countries and is a trusted therapy for clinicians in the management of OA.
Proven safe and effective, DUROLANE has more clinical studies than any other US single-injection HA, and has also been proven to provide greater reduction in OA knee pain versus Synvisc-One®.1,2 It has longer lasting pain relief versus a steroid injection, is safe and repeated use of DUROLANE does not increase the incidence of adverse events.3,4
DUROLANE is available in its original 3ml syringe for treatment of large joints and in a 1ml syringe, known as DUROLANE SJ, to enable treatment of small joints.* Both are produced using a natural, safe and proven technology called NASHA ® . This process yields a high molecular weight stabilized HA, which is a naturally occurring molecule that provides lubrication and cushioning in a normal joint.
“The US launch of DUROLANE in 2018 boosted our growth to more than 2 million treatments and we are very proud of this milestone. Still, there are many more patients to reach,” said John Nosenzo, Chief Commercial Officer, Bioventus. “In the US, more than 14 million people are afflicted with knee OA and osteoarthritis overall affects more than 240 million globally.5,6 Returning people to active lifestyles is our commitment to the market and we are pleased that DUROLANE is serving the needs of clinicians and the OA patients they treat.”
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the company on LinkedIn and Twitter.
Bioventus, the Bioventus logo, and DUROLANE are registered trademarks of Bioventus LLC. NASHA is a registered trademark. Synvisc-One and Synvisc are registered trademarks of Genzyme Corporation.
*DUROLANE SJ is not available in the US.
Summary of Indication for Use: DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen. Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Full prescribing information can be found in product labeling, at www.DUROLANE.com , or by contacting Bioventus Customer Service at 1-800-836-4080.
NOTE: The above indications presented are for the US market; indications may vary by country. Contact your local Bioventus representative or visit www.durolane.com/uk/selection for prescribing information specific to your market.
1. McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis. J Arthritis. 2013; 2(1):108. doi:10.4172/2167-7921.1000108. 2. DOF RPT-001111 3. Leighton R, Åkermark C, Therrien R, et. al. NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage. 2014; 22(1):17-25. 4. DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2017. 5. Arthritis Foundation. What is osteoarthritis? Accessed February 9, 2019. www.arthritis.org/about-arthritis/types/osteoarthritis/what-is-osteoarthritis.php 6. Hawker GA. Osteoarthritis is a serious disease. Clin Exp Rheumatol. 2019;37 Suppl 120(5):3-6.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005067/en/
Contact information
Thomas Hill
919-474-6715
thomas.hill@bioventusglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ADX and Its Listed Companies Connect with International Capital at Global Investor Roadshow in New York22.9.2026 15:01:00 EEST | Press release
The Abu Dhabi Securities Exchange (ADX) Group is heading to New York for its annual Global Investor Roadshow and Conference, held in collaboration with Morgan Stanley on 24 and 25 September 2026. This is part of ADX’s ongoing commitment and engagement outreach to institutional investors across key global financial centers. The ADX event in New York will highlight the investment opportunities Abu Dhabi’s capital markets offer through its leading listed companies, as the ADX supports Abu Dhabi’s long-term economic vision and sustainable economic growth as a global capital hub. H.E. Ghannam Butti Almazrouei, Chairman of the ADX, and Abdulla Salem Alnuaimi, Group Chief Executive Officer, will lead the delegation. They will be joined by senior management and investor relations officers from 14 ADX-listed companies. Direct discussions with management teams will enable investors to explore company fundamentals, competitive positioning, and investment propositions in greater depth. The delegat
Manhattan Associates Announces Editions TM for its Industry-Leading Solutions, Making Them Accessible at Every Stage of Growth22.9.2026 15:00:00 EEST | Press release
Manhattan Associates (NASDAQ: MANH), the global leader in supply chain commerce with unmatched AI capabilities, today announced the commercial launch of Editions for Manhattan Active® solutions. Editions provide a new way for companies of all sizes and across industries to partner with Manhattan. They are designed to help growing organizations make a durable, long-term technology decision from the start. As complexity increases, customers can unlock additional capabilities on the same platform, rather than starting over. Built for ActiveWarehouse™, ActiveTransportation™, ActiveStore™ and ActiveOrder™, on Manhattan’s award-winning ActivePlatform™, there are three Editions available: Essentials, Enterprise and Enterprise Premier. Regardless of the Edition selected for each solution, companies gain access to the power of a unified platform, AI capabilities and continuous innovation that underpin some of the world’s most complex supply chain and commerce operations. Editions are not separa
Who Decides What’s Safe Online? Trust Issues Returns for Season 222.9.2026 15:00:00 EEST | Press release
WebPurify, an IntouchCX Company specializing in trust and safety, has launched the season 2 of Trust Issues, a podcast exploring the technology, policies, and human decisions shaping the future of online safety. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922209613/en/ WebPurify, an IntouchCX Company specializing in trust and safety, has launched the season 2 of Trust Issues, a podcast exploring the technology, policies, and human decisions shaping the future of online safety. Who ultimately decides what stays up and what comes down in digital spaces? Season 2 answers that question by examining how AI capabilities, shifting market place regulations, human judgement and operational constraints intersect. Moving beyond simple technical solutions, each episode goes behind the scenes of the complex pressures facing digital platforms today, from cost efficiencies to high stake compliance, and the strategies leaders use to b
New CSC Report Finds Heightened Concern for IP Infringement as Expanding Domain Ecosystems Increase Operational Pressure22.9.2026 15:00:00 EEST | Press release
CSC, an enterprise-class domain registrar and global provider of domain security, brand protection, and fraud protection services, today released new research examining how senior executives specializing in intellectual property (IP) law are responding to growing online infringement risks and preparing for the expansion of the domain namespace. According to CSC’s The State of Online IP Risk 2026 report, 96% of senior IP law executives are concerned about the threat of IP infringements, with 90% noting AI-enabled systems are increasing online IP infringements. To identify current and emerging IP risks and to understand how organizations plan to respond, CSC surveyed 300 senior executives specializing in IP law—including general counsels, chief legal officers, and chief technology officers—in Q2 2026. This research is timely following the Internet Corporation for Assigned Names and Numbers (ICANN)’s latest round of generic top-level domain (gTLD) applications, which closed on August 12,
INNIO Receives Credit Rating Upgrades and Reaffirms Financial Policy to Support Profitable Growth22.9.2026 15:00:00 EEST | Press release
INNIO N.V. (Nasdaq: INIO) (“INNIO” or the “Company”) today announced that Fitch Ratings has upgraded the Company’s credit ratings, following a recent upgrade by Moody’s Ratings. INNIO also reaffirmed its financial policy framework, which supports investment in profitable growth while continuing to strengthen the Company’s balance sheet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922051908/en/ INNIO Receives Credit Rating Upgrades and Reaffirms Financial Policy to Support Profitable Growth Credit rating upgrades Moody’s upgraded INNIO’s Corporate Family Rating by one notch to Ba3 from B1 and revised the outlook to positive from stable. Fitch Ratings upgraded INNIO’s Long-Term Issuer Default Rating by two notches to BB from B+, with a stable outlook. Fitch also upgraded INNIO’s senior secured debt rating to BB+ from B+. These upgrades reflect INNIO’s strong operating performance and cash flow generation, supported by fa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom